Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma

References

• Abbas AK, Lichtman AH, Pober JS.Cellular and Molecular Immunology (3rd Edition). Saunders, Philadelphia, USA, (1997).
   Google Scholar
• Paul WE. Fundamental Immunology (4th ). Lippincott, Williams andWilkins. Philadelphia, USA, (1999).
   Google Scholar
• Lynch RG, Graff RJ, Sirisinha S, Simms, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl . Sc]. USA 69,1540–1544 (1972).
   PubMed Web of Science ®Google Scholar
• Stevenson GT, Stevenson FK. Antibody to molecularly-defined antigen confined to a tumor cell surface. Nature 254, 714–716 (1974).
   Google Scholar
• Boon T, Cerottini JC, Van den Eynde B, der Bruggen P, Van Pei A. Tumor antigens recognized by T lymphocytes. Ann. Rev. Iminunol. 12, 337–365 (1994).
   PubMed Web of Science ®Google Scholar
• Cheever MA, Disis ML, Bernhard H et al to oncogenic proteins. Immunol Rev 145, 33–59 (1995).
   PubMed Web of Science ®Google Scholar
• Henderson RA, Finn 0J. Human tumor are ready to fly. Adv. Immunol 62, 217–256 (1996).
   Google Scholar
• Syrengelas AD, Levy R. DNA vaccination the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J: Immunol 162, 4790–4795 (1999).
   PubMedGoogle Scholar
• Schultze JL, Nadler LM. T cell mediated for B cell lymphoma. Mot. Med. 77, 322–331 (1999).
   PubMedGoogle Scholar
• Raffeld M, Neckers L, Longo DL, Cossman J. Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype. N Engl. I Med. 312, 1653–1658 (1985).
   PubMed Web of Science ®Google Scholar
• Meeker T, Lowder J, Cleary ML. of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl. I Med. 312, 1658–1665 (1985).
   Google Scholar
• Hsu FJ, Caspar CB, Czerwinski D. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma — long-term results of a clinical trial. Blood 89, 3129–3135 (1997).
   Google Scholar
• ••The series of patients immunized with idiotype vaccines featuring the longest follow-up.
   Google Scholar
• Bendandi M, Gocke CD, Kobrin CB. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Merl 5, 1171–1177 (1999).
   Google Scholar
• ••A Phase II clinical trial featuring the firstdemonstration of vaccine-induced molecular remissions.
   Google Scholar
• Dorfman DM, Schultze JL, Shahsafaei A et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 90, 4297–4306 (1997).
   PubMed Web of Science ®Google Scholar
• Kwak LW, Campbell MJ, Czerwinski DK, S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. Merl 327, 1209–1215 (1992).
   PubMed Web of Science ®Google Scholar
• ••The first demonstration that humans canbe immunized against their own tumor antigens.
   Google Scholar
• Kwak LW, Taub DD, Duffey PL et al of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345, 1016–1020 (1995).
   PubMed Web of Science ®Google Scholar
• Bergenbrant S, Yi Q, Osterborg A et al. of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. BE j Haematol 92, 840–846 (1996).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Yi Q, Henriksson L et al. immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced Type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Bloor191, 2459–2466 (1998).
   Google Scholar
• Reichardt VL, Okada CY, Liso A et al. vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma — a feasibility study. B/ooc/93, 2411–2419 (1999).
   Google Scholar
• Massaia M, Borrione P, Battaglio S et al. vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. B/ooc/94, 673–683 (1999).
   Google Scholar
• Lim SH, Bailey-Wood R. Idiotypic protein- dendritic cell vaccination in multiple myeloma. Int.j Cancer 83, 215–222 (1999).
   PubMed Web of Science ®Google Scholar
• Campbell MJ, Carroll W Kon S et al vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin and its molecular subunits. J. Iminunol. 139, 2825–2833 (1987).
   Google Scholar
• Campbell MJ, Esserman L, Levy R. of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. Immunol 141, 3227–3233 (1988).
   Google Scholar
• Harris NL, Jaffe ES, Stein H et al. A revised -American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84, 1361–1392 (1994).
   PubMed Web of Science ®Google Scholar
• Horning SJ, Rosenberg SA. The natural of initially untreated low-grade non-Hodgkin's lymphomas. N Engl. J. Med 311, 1471–1475 (1984).
   PubMed Web of Science ®Google Scholar
• Bendandi M, Longo DL. Biologic therapy lymphoma. CU17: Opin. Oncol 11, 343–350 (1999).
   Google Scholar
• Carroll WL, Thielemans K, Dilley J, Levy . Mouse x human heterohybridomas as fusion partners with human B cell tumors. Immunol Methods 89, 61–72 (1986).
   Google Scholar
• Kobrin CB, Kwak LW Development of strategies for the treatment of B-cell malignancies. Cancer Invest. 15, 577–587 (1997).
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Kitamura K, Maloney DG, R. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J. Immunol 138, 1289–1296 (1987).
   Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. Exp. Merl 179, 1109–1118 (1994).
   Google Scholar
• Timmerman JM, Czerwinski DK, van A et al A Phase I/II trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin's lymphoma (NHL). Proceedings of the 42nd Annual Meeting of the American Society of . San Francisco, USA, Abstract 2481 (2000).
   Google Scholar
• •The first presentation on the use of soluble protein Id vaccines obtained via recombinant technology rather then hybridomas.
   Google Scholar
• Kwak LW Young HA, Pennington RVV, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/ macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl Acad Sc]. USA 93, 10972–10977 (1996).
   PubMedGoogle Scholar
• Disis ML, Bernhard H, Shiota FM et al -macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88, 202–210 (1996).
   PubMed Web of Science ®Google Scholar
• de Gruijl TD, Curiel DT Cancer vaccine get bigger and better. Nature Merl 5, 1124–1125 (1999).
   PubMedGoogle Scholar
• Stevenson FK, Zhu D, King CA, Ashworth, Kumar S, Hawkins RE. Idiotypic DNA vaccines against B-cell lymphoma. Rev 145, 211–228 (1995).
   Google Scholar
• Hawkins RE, Zhu D, Ovecka M et al. vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. B/ooc/83, 3279–3288 (1994).
   Google Scholar
• King CA, Spellerberg MB, Zhu D et al. vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nature Med. 4, 1281–1286 (1998).
   PubMed Web of Science ®Google Scholar
• Stevenson FK. Vaccine strategies in lymphoma. In: Education Program Book ASH, Washington, USA, (1999).
   Google Scholar
• Allison AC, Byars NE. An adjuvant that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol Meth. 95, 157–68 (1986).
   PubMed Web of Science ®Google Scholar
• Nelson EL, Li X, Hsu FJ et al. Tumor-, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88, 580–589 (1996).
   PubMed Web of Science ®Google Scholar
• Bendandi M, Kwak LW Translational of patient-specific vaccination for follicular lymphoma. Haematologica 84, S70–72 (1999).
   PubMedGoogle Scholar
• Nestle FO, Alijagic S, Gullet M et al. of melanoma patients with peptide- or tumor lysate-pulsed dendritic . Nature Med. 4,328–332 (1998).
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Mobilizing cells for tolerance, priming and chronic inflammation. I Exp. Med. 189, 611–614 (1999).
   PubMedGoogle Scholar
• Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2,52–58 (1996).
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Davis TA, Hsu FJ et al. -pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immunological responses in 26 patients. B/ooc/94\(Suppl. 1), Abstract 1712 (1999).
   Google Scholar
• Hsu FJ, Komarovskaya M, Song B, Doyon . Active immunotherapy of patients with lymphoma with sequential dendritic cell and protein/adjuvant idiotype vaccines. B/ooc/94\(Suppl. 1), Abstract 1713 (1999).
   Google Scholar
• Timmerman JM, Hsu FJ, Davis TA et al. of follicular lymphoma following vaccination with idiotype protein coupled to keyhole limpet hemocyanin (Id-KLH) and idiotype-pulsed dendritic cells. B/ooc/96\(Suppl. 1), Abstract 2185 (2000).
   Google Scholar
• Hawkins RE, Russell SJ, Marcus R et al. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic . CRC NO: 92/33. Protocol NO: PH1/027. Hum. Gene Ther. 8,1287-1299 (1997).
   Google Scholar
• Keating MJ. Purine analogs in the of indolent lymphoproliferative disorders. ILematologica 84, S28–32 (1999).
   PubMedGoogle Scholar
• Maloney DG. Rituximab anti-CD20 antibody therapy of B-cell non-Hodgkin's lymphoma. ILematologica 84, S55–57 (1999).
   Google Scholar
• Press OW Radioimmunotherapy of non- 's lymphomas. ILematologica 84, S63–66 (1999).
   Google Scholar
• Gribben JG. Adoptive immunotherapy for -cell lymphoma. ILematologica 84, S67–69 (1999).
   PubMedGoogle Scholar
• Levitsky HI, Montgomery J, Ahmadzadeh et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J: Immund 156, 3858–3865 (1996).
   PubMed Web of Science ®Google Scholar
• Schultze JL, Cardoso AA, Freeman GJ et al. lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Nat' Acad. Sc]. USA 92,8200–8204 (1995).
   PubMed Web of Science ®Google Scholar
• Caspar CB, Levy S, Levy R. Idiotype for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. B/ooc/90, 3699–3706 (1997).
   Google Scholar
• Gribben JG, Freedman As, Woo SD et al. advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bc1-2 have residual cells containing the bc1-2 rearrangement at evaluation and after treatment. B/ooc/78,3275–3280 (1991).
   Google Scholar
• Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. The clinical significance of molecular response in indolent follicular lymphomas. B/ooc/91, 2955–2960 (1998).
   Google Scholar
• Stevenson FK, Gordon J. Immunization idiotypic immunoglobulin protects against development of B lymphocytic leukaemia, but emerging tumor cells can evade antibody attack by modulation. J: Immund 130,970–973 (1983).
   PubMed Web of Science ®Google Scholar
• George AJ, Tuft AL, Stevenson FK. Anti- mechanisms involved in suppression of a mouse B cell lymphoma, BCD. Immund 138,628–634 (1987).
   Google Scholar